201 related articles for article (PubMed ID: 9275028)
1. Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin.
Screnci D; Er HM; Hambley TW; Galettis P; Brouwer W; McKeage MJ
Br J Cancer; 1997; 76(4):502-10. PubMed ID: 9275028
[TBL] [Abstract][Full Text] [Related]
2. Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model.
Luo FR; Wyrick SD; Chaney SG
Cancer Chemother Pharmacol; 1999; 44(1):29-38. PubMed ID: 10367746
[TBL] [Abstract][Full Text] [Related]
3. Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs.
Screnci D; McKeage MJ; Galettis P; Hambley TW; Palmer BD; Baguley BC
Br J Cancer; 2000 Feb; 82(4):966-72. PubMed ID: 10732773
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats.
Luo FR; Wyrick SD; Chaney SG
Cancer Chemother Pharmacol; 1999; 44(1):19-28. PubMed ID: 10367745
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity.
Shord SS; Bernard SA; Lindley C; Blodgett A; Mehta V; Churchel MA; Poole M; Pescatore SL; Luo FR; Chaney SG
Anticancer Res; 2002; 22(4):2301-9. PubMed ID: 12174918
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells.
Luo FR; Wyrick SD; Chaney SG
Oncol Res; 1998; 10(11-12):595-603. PubMed ID: 10367941
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the reactivity of oxaliplatin, pt(diaminocyclohexane)Cl2 and pt(diaminocyclohexane1)(OH2)2(2+) with guanosine and L-methionine.
Verstraete S; Heudi O; Cailleux A; Allain P
J Inorg Biochem; 2001 Mar; 84(1-2):129-35. PubMed ID: 11330471
[TBL] [Abstract][Full Text] [Related]
8. Biotransformations of oxaliplatin in rat blood in vitro.
Luo FR; Wyrick SD; Chaney SG
J Biochem Mol Toxicol; 1999; 13(3-4):159-69. PubMed ID: 10098901
[TBL] [Abstract][Full Text] [Related]
9. Differential cytotoxicity, uptake and DNA binding of tetraplatin and analogous isomers in sensitive and resistant cancer cell lines.
Kido Y; Khokhar AR; Siddik ZH
Anticancer Drugs; 1993 Apr; 4(2):251-8. PubMed ID: 8490203
[TBL] [Abstract][Full Text] [Related]
10. Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands.
Kido Y; Khokhar AR; al-Baker S; Siddik ZH
Cancer Res; 1993 Oct; 53(19):4567-72. PubMed ID: 8402629
[TBL] [Abstract][Full Text] [Related]
11. High-performance liquid chromatographic separation of the biotransformation products of oxaliplatin.
Luo FR; Yen TY; Wyrick SD; Chaney SG
J Chromatogr B Biomed Sci Appl; 1999 Mar; 724(2):345-56. PubMed ID: 10219677
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxicity of platinum(IV) and platinum(II) complexes containing 1R,2R-cyclohexanediamine as a ligand.
Yamashita T; Hirose J; Noji M; Saito R; Tomida H; Kidani Y
Biol Pharm Bull; 1993 Oct; 16(10):1014-8. PubMed ID: 8287030
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers.
Pendyala L; Kidani Y; Perez R; Wilkes J; Bernacki RJ; Creaven PJ
Cancer Lett; 1995 Nov; 97(2):177-84. PubMed ID: 7497460
[TBL] [Abstract][Full Text] [Related]
14. The chemistry and biology of platinum complexes with the 1,2-diaminocyclohexane carrier ligand (review).
Chaney S
Int J Oncol; 1995 Jun; 6(6):1291-305. PubMed ID: 21556672
[TBL] [Abstract][Full Text] [Related]
15. Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model.
Holmes J; Stanko J; Varchenko M; Ding H; Madden VJ; Bagnell CR; Wyrick SD; Chaney SG
Toxicol Sci; 1998 Dec; 46(2):342-51. PubMed ID: 10048138
[TBL] [Abstract][Full Text] [Related]
16. East-west fusion-necrosis and apoptosis acting in concert by demethylcantharidin-integrated platinum complexes.
Pang SK; So WK; Ho YP; Au-Yeung CF
Anticancer Agents Med Chem; 2014 Jun; 14(5):756-61. PubMed ID: 24476313
[TBL] [Abstract][Full Text] [Related]
17. Differential antitumor activity and toxicity of isomeric 1,2-diaminocyclohexane platinum (II) complexes.
Siddik ZH; al-Baker S; Burditt TL; Khokhar AR
J Cancer Res Clin Oncol; 1993; 120(1-2):12-6. PubMed ID: 8270602
[TBL] [Abstract][Full Text] [Related]
18. Nucleolar damage correlates with neurotoxicity induced by different platinum drugs.
McKeage MJ; Hsu T; Screnci D; Haddad G; Baguley BC
Br J Cancer; 2001 Oct; 85(8):1219-25. PubMed ID: 11710838
[TBL] [Abstract][Full Text] [Related]
19. Organ-specific biotransformation of ormaplatin in the Fischer 344 rat.
Thompson DC; Vaisman A; Sakata MK; Wyrick SD; Holbrook DJ; Chaney SG
Cancer Chemother Pharmacol; 1995; 36(5):439-47. PubMed ID: 7634386
[TBL] [Abstract][Full Text] [Related]
20. Role of carrier ligand in platinum resistance in L1210 cells.
Gibbons GR; Page JD; Mauldin SK; Husain I; Chaney SG
Cancer Res; 1990 Oct; 50(20):6497-501. PubMed ID: 2208108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
